KFDA approves Vimpat as adjunct antiepileptic drug

Published: 2010-08-19 06:59:00

Updated: 2010-08-19 06:59:00

The Korea Food and Drug Administration said on August 6 it has approved UCB's Vimpat (lacosamide) for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.

Vimpat is an orally-available anticonvulsant. It selectively enhances slow inactivation of sodium channels and...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK